Peter Powchik Insider Trading for August 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Peter Powchik.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Overview of insider trading of Peter Powchik for August 2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 270.43 | 10,000 | 2,704,300 | 30,000 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 179.13 | 14,625 | 2,619,776 | 29,250 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 52.03 | 8,000 | 416,240 | 6,079 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 52.03 | 23,000 | 1,196,690 | 14,079 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Option Exercise | M | 30.63 | 4,736 | 145,064 | 0 | |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 578.63 | 1,500 | 867,945 | 15,821 | 17.3 K to 15.8 K (-8.66 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 577.75 | 2,258 | 1,304,560 | 17,321 | 19.6 K to 17.3 K (-11.53 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 576.65 | 2,004 | 1,155,607 | 19,579 | 21.6 K to 19.6 K (-9.29 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 575.47 | 700 | 402,829 | 21,583 | 22.3 K to 21.6 K (-3.14 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 574.75 | 900 | 517,275 | 22,283 | 23.2 K to 22.3 K (-3.88 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 573.64 | 2,717 | 1,558,580 | 23,183 | 25.9 K to 23.2 K (-10.49 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 572.60 | 2,800 | 1,603,280 | 25,900 | 28.7 K to 25.9 K (-9.76 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 571.54 | 5,598 | 3,199,481 | 28,700 | 34.3 K to 28.7 K (-16.32 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 570.63 | 3,603 | 2,055,980 | 34,298 | 37.9 K to 34.3 K (-9.51 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Sell | S | 569.63 | 1,405 | 800,330 | 37,901 | 39.3 K to 37.9 K (-3.57 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 2,146 | 1,243,285 | 39,306 | 41.5 K to 39.3 K (-5.18 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 250 | 144,838 | 41,452 | 41.7 K to 41.5 K (-0.60 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 30.63 | 4,736 | 145,064 | 41,702 | 37 K to 41.7 K (+12.81 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 3,755 | 2,175,459 | 36,966 | 40.7 K to 37 K (-9.22 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 718 | 415,973 | 40,721 | 41.4 K to 40.7 K (-1.73 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 52.03 | 8,000 | 416,240 | 41,439 | 33.4 K to 41.4 K (+23.92 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 10,795 | 6,254,083 | 33,439 | 44.2 K to 33.4 K (-24.40 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 2,065 | 1,196,358 | 44,234 | 46.3 K to 44.2 K (-4.46 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 52.03 | 23,000 | 1,196,690 | 46,299 | 23.3 K to 46.3 K (+98.72 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 5,210 | 3,018,414 | 23,299 | 28.5 K to 23.3 K (-18.27 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 4,521 | 2,619,241 | 28,509 | 33 K to 28.5 K (-13.69 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 179.13 | 14,625 | 2,619,776 | 33,030 | 18.4 K to 33 K (+79.46 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 2,749 | 1,592,633 | 18,405 | 21.2 K to 18.4 K (-13.00 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Payment of Exercise | F | 579.35 | 4,667 | 2,703,826 | 21,154 | 25.8 K to 21.2 K (-18.07 %) |
| Aug 17 2015 | REGN | REGENERON PHARMACE ... | Powchik Peter | SVP Clinical Develo ... | Buy | M | 270.43 | 10,000 | 2,704,300 | 25,821 | 15.8 K to 25.8 K (+63.21 %) |